ClotChip® is a class 2 medical device that has received FDA breakthrough device designation in March 2020, and is currently in clinical trials. A list of feasibility studies on the ClotChip® sensor include the following:

Pilot Studies

Phase I Clinical Study

ClotChip® Sensitivity in Target Specific oral Anticoagulants
The U.S. Department of Veterans Affairs, Cleveland, OH
Status: enrollment closed ; N=176
Assessment of whole blood coagulation with a microfluidic dielectric sensor published in Journal of Thrombosis and Haemostasis, 16: 2050–205

1 2